Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects

Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the efficacy of 4 treatment regimens of Cat-PAD in cat allergic subjects following challenge to cat allergen in an environmental exposure chamber (EEC).

Timeline

Start

2008-08

Primary completion

2009-04

Completion

2009-05

Drugs

Indications

No indication recorded.